SLC7A11 Pan-Cancer Immunotherapy Biomarker Analysis with TNBC Validation

Data Sheet 1_An integrated analysis of SLC7A11 as a pan-cancer immunotherapeutic biomarker with experimental validation of its regulation by miR-148b-3p in breast cancer.zip was authored by Songchen Zhao and last updated on 2026-05-19. It contains results from a pan-cancer analysis of the SLC7A11 gene's role in tumor immunity and ferroptosis, validated via in vitro experiments in triple-negative breast cancer cell models. The dataset is 2.1 MB in size and shared under a CC-BY-4.0 license.

Use Cases

• Identify potential immunotherapy response biomarkers based on SLC7A11 expression associations with tumor mutational burden and PD-L1 levels.
• Investigate ferroptosis resistance mechanisms in cancer based on the described link between SLC7A11, glutathione levels, and lipid peroxidation.
• Validate miRNA-gene regulatory networks in breast cancer using the described SLC7A11-miR-148b-3p axis.
• Perform survival analysis in immunotherapy-treated cohorts based on SLC7A11 expression levels.
• Analyze immune infiltration patterns across cancer types in relation to SLC7A11 expression.

Strengths

• Analysis includes data from TCGA and GTEx, which are major public cancer genomics resources.
• Experimental validation was performed in two triple-negative breast cancer cell lines (MDA-MB-231 and MDA-MB-468).
• Pan-cancer scope covers over 88% of tumor types according to the description.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

Songchen Zhao via figshare.

Collection Method

Systematic analysis of public data (TCGA, GTEx) combined with in vitro experiments.

Freshness

Last updated 2026-05-19 05:38:47; freshness should be verified.